Phase composition control of calcium phosphate nanoparticles for tunable drug delivery kinetics and treatment of osteomyelitis. II. Antibacterial and osteoblastic response

Journal of Biomedical Materials Research - Part A

Volumn 101 A, Issue 5, 2013, Pages 1427-1436

  Uskokovic̈, Vuk ^a   Desai, Tejal A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

calcium phosphate; drug delivery; osteoblasts; osteogenesis; osteomyelitis

Indexed keywords

ANTI-BACTERIAL PERFORMANCE; ANTIMICROBIAL PERFORMANCE; CALCIUM PHOSPHATE NANOPARTICLES; MINIMAL INHIBITORY CONCENTRATION; MULTI-FUNCTIONAL MATERIALS; OSTEOGENESIS; OSTEOMYELITIS; SUSTAINED DRUG RELEASE;

BACTERIA; CALCIUM PHOSPHATE; CELL CULTURE; DRUG DELIVERY; OSTEOBLASTS; SURGERY; TISSUE;

ANTIBIOTICS;

CALCIUM PHOSPHATE; CLINDAMYCIN PHOSPHATE; NANOPARTICLE;

ANIMAL CELL; ARTICLE; DRUG ADSORPTION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG SOLUBILITY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOMYELITIS; STAPHYLOCOCCUS AUREUS; SUSTAINED DRUG RELEASE;

3T3 CELLS; ANIMALS; ANTI-BACTERIAL AGENTS; CALCIUM PHOSPHATES; CLINDAMYCIN; DELAYED-ACTION PREPARATIONS; HUMANS; MICE; NANOPARTICLES; OSTEOBLASTS; OSTEOMYELITIS; SOLUBILITY; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84875415920     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.34437     Document Type: Article

References (54)

1. US Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, Office of the Surgeon General; 2004.
2. Del Pozo JL, Patel R,. Infection associated with prosthetic joints. New Eng J Med 2009; 361: 787-794.
3. Hatzenbuehler J, Pulling TJ,. Diagnosis and management of osteomyelitis. Am Fam Phys 2011; 84: 1027-1033.
4. Kundu B, Nandi SK, Dasgupta S, Datta S, Mukherjee F, Roy S, Singh AK, Mandal TK, Das F, Bhattacharya R, Basu D,. Macro-to-micro porous special bioactive glass and ceftriaxone-sulbactam composite drug delivery system for treatment of chronic osteomyelitis: an investigation through in vitro and in vivo animal trial. J Mat Sci Mat Med 2011; 22: 705-720.
5. Waknis V, Jonnalagadda S,. Novel poly- DL -lactide-polycaprolactone copolymer based flexible drug delivery system for sustained release of ciprofloxacin. Drug Deliv 2011; 18: 236-245.
6. Peng KT, Chen CF, Chu IM, Li, YM, Hsu WH, Hsu RW, Chang PJ,. Treatment of osteomyelitis with teicoplanin-encapsulated biodegradable thermosensitive hydrogel nanoparticles. Biomaterials 2010; 31: 5227-5236.
7. El-Ghannam A, Jahed K, Govindaswami M,. Resorbable bioactive ceramic for treatment of bone infection. J Biomed Mat Res A 2010; 94A: 308-316.
8. Kanellakopoulou K, Giamarellos-Bourboulis EJ,. Carrier systems for the local delivery of antibiotics in bone infections. Drugs 2000; 59: 1223-1232.
9. Uskokovic̈ V, Uskokovic̈ DP,. Nanosized hydroxyapatite and other calcium phosphates: Chemistry of formation and application as drug and gene delivery agents. J Biomed Mat Res B 2011; 96B: 152-191.
10. Dorozhkin SV,. Calcium Orthophosphates in Nature, Biology and Medicine. Materials 2009; 2: 399-498.
11. Neto AHC, Machado D, Yano CL, Ferreira CV,. Antioxidant defense and apoptotic effectors in ascorbic acid and β-glycerophosphate-induced osteoblastic differentiation. Dev Grow Diff 2011; 53: 88-96.
12. Pfaffl MW,. A new mathematical model for relative quantification in real-time RT-PCR. Nucl Acids Res 2001; 29: 45e-45e.
13. Guay D,. Update on clindamycin in the management of bacterial, fungal and protozoal infections. Exp Opin Pharmacother 2007; 8: 2401-2444.
14. Buffie CG, Jarchum I, Equinda M, Lipuma L, Gobourne A, Viale A, Ubeda C, Xavier J, Pamer EG,. Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to clostridium difficile-induced colitis. Infect Immun 2011; 80: 62-73.
15. Addy LD, Martin MV,. Clindamycin and dentistry. BDJ 2005; 199: 23-26.
16. Vukomanovic̈ M, Škapin SD, Jančar B, Maksin T, Ignjatovic̈ N, Uskokovic̈ V, Uskokovic̈ D,. Poly(D,L -lactide-co-glycolide)/hydroxyapatite core-shell nanospheres. Part 1. Colloid Surf B 2011; 82: 404-413.
17. Aarts HJM, Guerra B, Malorny B,. Molecular methods for detection of antibiotic resistance. In:, Aarestrup FM, editor. Antimicrobial Resistance in Bacteria of Animal Origin. Washington, DC: American Society for Microbiology Press; 2006. p 55.
18. Pace JL, Rupp ME, Finch RG,. Biofilms, Infection, and Antimicrobial Therapy. Boca Raton, FL: CRC; 2006.
19. Quintiliani R, Quintiliani R,. Pharmacokinetics/pharmacodynamics for critical care clinicians. Crit Care Clin 2008; 24: 335-348.
20. Kovtun A, Kozlova D, Ganesan K, Biewald C, Seipold N, Gaengler P, Arnold WH, Epple M,. Chlorhexidine-loaded calcium phosphate nanoparticles for dental maintenance treatment: combination of mineralising and antibacterial effects. RSC Adv 2012; 2: 870-875.
21. Chalmers G, Kozak GK, Hilyer E, Reid-Smith RJ, Boerlin P,. Low minimum inhibitory concentrations associated with the tetracycline-resistance gene tet(C) in E coli. Can J Vet Res 2010; 74: 145-148.
22. Reeves DS, Holt HA, Phillips I, King A, Miles RS, Paton R, Wise R, Andrews JM,. Activity of clindamycin against S aureus and S epidermidis from four UK centres. J Antimicrob Chemother 1991; 27: 469-474.
23. Gallagher J, MacDougall C,. Antibiotics Simplified. Sudbury, MA: Jones and Bartlett Publishers; 2009.
24. Lemaire S, Van Bambeke F, Pierard D, Appelbaum PC, Tulkens PM,. Activity of fusidic acid against extracellular and intracellular Staphylococcus aureus: influence of pH and comparison with linezolid and clindamycin. Clin Infect Dis 2011; 52: S493-S503.
25. Connors KA, Amidon GL, Stella VJ,. Chemical Stability of Pharmaceuticals. Hoboken, NJ: Wiley; 1986.
26. Weinrick B, Dunman PM, McAleese F, Murphy E, Projan SJ, Fang Y, Novick RP,. Effect of mild acid on gene expression in Staphylococcus aureus. J Bacteriol 2004; 186: 8407-8423.
27. Baudoux P, Bles N, Lemaire S, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F,. Combined effect of pH and concentration on the activities of gentamicin and oxacillin against Staphylococcus aureus in pharmacodynamic models of extracellular and intracellular infections. J Antimicrob Chemother 2006; 59: 246-253.
28. Morozowich W, Karnes HA,. Case Study: clindamycin 2-Phosphate. Biotech Pharma Asp 2007; 5: 1207-1219.
29. Iafisco M, Palazzo B, Martra G, Margiotta N, Piccinonna S, Natile G, Gandin V, Marzano C, Roveri N,. Nanocrystalline carbonate-apatites: role of Ca/P ratio on the upload and release of anticancer platinum bisphosphonates. Nanoscale 2012; 4: 206-217.
30. Johnson ML, Uhrich KE,. Concurrent release of admixed antimicrobials and salicylic acid from salicylate-based poly(anhydride-esters). J Biomed Mat Res A 2009; 91A: 671-678.
31. Gelperina S, Kisich K, Iseman MD, Heifets L,. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med 2005; 172: 1487-1490.
32. Radi S, Ducheyne P,. Nanostructural control of implantabale xerogels for the controlled release of biomolecules. NATO Sci Series II, Math Phys Chem 2004; 171: 59-74.
33. Mourino V, Boccaccini AR,. Bone tissue engineering therapeutics: controlled drug delivery in three-dimensional scaffolds. J Royal Soc Interface 2009; 7: 209-227.
34. Vukomanovic̈ M, Škapin SD, Poljanšek I, Zagar E, Kralj B, Ignjatovic̈ N, Uskokovic̈ D,. Poly(D,L -lactide-co-glycolide)/ hydroxyapatite core-shell nanosphere. Part 2. Simultaneous release of a drug and a prodrug (clindamycin and clindamycin phosphate). Colloids Surf B 2011; 82: 414-421.
35. Cameron DR, Howden BP, Peleg AY,. The interface between antibiotic resistance and virulence in Staphylococcus aureus and its impact upon clinical outcomes. Clin Infect Dis 2011, 53: 576-582.
36. Pigrau C, Almirante B, Rodriguez D, Larrosa N, Raspall G, Pahissa A,. Osteomyelitis of the jaw: resistance to clindamycin in patients with prior antibiotics exposure. Eur J Clin Microbiol Infect Dis 2008; 28: 317-323.
37. Tamimi F, Torres J, Bassett D, Barralet J, Cabarcos EL,. Resorption of monetite granules in alveolar bone defects in human patients. Biomaterials 2010; 31: 2762-2769.
38. 4 on the proliferation, osteogenic differentiation and mineralization of human periodontal ligament cells. J Periodontal Res 2012; 47: 374-382.
39. Varanasi VG, Owyoung JB, Saiz E, Marshall SJ, Marshall GW, Loomer PM,. The ionic products of bioactive glass particle dissolution enhance periodontal ligament fibroblast osteocalcin expression and enhance early mineralized tissue development. J Biomed Mater Res A 2011; 98A: 177-184.
40. Bramer JAM, van Linge JH, Grimer RJ, Scholten RJPM,. Prognostic factors in localized extremity osteosarcoma: a systematic review. Eur J Surg Oncol 2009; 235: 1030-1036.
41. Xu L, Lv K, Zhang W, Zhang X, Jiang X, Zhang F,. The healing of critical-size calvarial bone defects in rat with rhPDGF-BB, BMSCs, and β-TCP scaffolds. J Mater Sci Mater Med 2012; 23: 1073-1084.
42. Sakamoto W, Isomura H, Fujie K, Deyama Y, Kato A, Nishihira J, Izumi H,. Homocysteine attenuates the expression of osteocalcin but enhances osteopontin in MC3T3-E1 preosteoblastic cells. Biochim Biophys Acta 2005; 1740: 12-16.
43. Huang W, Carlsen B, Rudkin G, Berry M, Ishida K, Yamaguchi DT, Miller TA,. Osteopontin is a negative regulator of proliferation and differentiation in MC3T3-E1 pre-osteoblastic cells. Bone 2004; 34: 799-808.
44. Sodek J, Ganss B, McKee MD,. Osteopontin. Crit Rev Oral Biol Med 2000; 11: 279-303.
45. Carbonare LD, Innamorati G, Valenti MT,. Transcription factor Runx2 and its application to bone tissue engineering. Stem Cell Rev 2012; 8: 891-897.
46. Naal FD, Salzmann GM, von Knoch F, Tuebel J, Diehl P, Gradinger R, Schauwecker J,. The effects of clindamycin on human osteoblasts in vitro. Arch Orthop Trauma Surg 2008; 128: 317-323.
47. Duewelhenke N, Krut O, Eysel P,. Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines. Antimicrob Agent Chemother 2006; 51: 54-63.
48. Ince A, Schütze N, Hendrich C, Thull R, Eulert J, Löhr JF,. In vitro investigation of orthopedic titanium-coated and brushite-coated surfaces using human osteoblasts in the presence of gentamycin. J Arthroplasty 2008; 23: 762-771.
49. Antoci V, Adams CS, Hickok NJ, Shapiro IM, Parvizi J,. Antibiotics for local delivery systems cause skeletal cell toxicity in vitro. Clin Orthop Relat Res 2007; 462: 200-206.
50. Holtom PD, Pavkovic SA, Bravos PD, Patzakis MJ, Shepherd LE, Frenkel B,. Inhibitory effects of the quinolone antibiotics trovafloxacin, ciprofloxacin, and levofloxacin on osteoblastic cells in vitro. J Orthop Res 2000; 18: 721-727.
51. Almazin SM, Dziak R, Andreana S, Ciancio SG,. The effect of doxycycline hyclate, chlorhexidine gluconate, and minocycline hydrochloride on osteoblastic proliferation and differentiation in vitro. J Periodontol 2009; 80: 999-1005.
52. Ince A, Schütze N, Hendrich C, Thull R, Eulert J, Löhr JF,. Effect of polyhexanide and gentamycin on human osteoblasts and endothelial cells. Swiss Med Wkly 2007; 137: 139-145.
53. Isefuku S, Joyner CJ, Simpson AHRW,. Gentamicin may have an adverse effect on osteogenesis. J Orthop Trauma 2003; 17; 212-216.
54. Adams K, Couch L, Cierny G, Calhoun J, Mader JT,. In vitro and in vivo evaluation of antibiotic diffusion for antibiotic-impregnated polymethylmethacrylate beads. Clin Orthop 1992; 278: 244-252.